Drug combo shows promise for tough blood cancer
NCT ID NCT02159755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the safety and best dose of combining ibrutinib and palbociclib in 28 patients with mantle cell lymphoma that has come back after treatment. Both drugs block enzymes that help cancer cells grow. The study aims to find a dose that is safe enough to test in larger trials and to see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib and palbociclib (two cancer drugs)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for patients with mantle cell lymphoma that has returned after prior therapy.
What could go wrong
This is a very early Phase I trial with only 28 participants, focused on safety and dosing. It is too small to confirm benefit, and side effects from combining two drugs are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States